Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 6:2018:5682078.
doi: 10.1155/2018/5682078. eCollection 2018.

Update on the Treatment of Metastatic Urothelial Carcinoma

Nedal Bukhari  1 , Humaid O Al-Shamsi  2 , Faisal Azam  1
Affiliations
Review

Update on the Treatment of Metastatic Urothelial Carcinoma

Nedal Bukhari et al. ScientificWorldJournal. .

Abstract

Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.

PubMed Disclaimer

References

    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology. 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Bladder cancer risk factors. Bladder Cancer Risk Factors. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-....
    1. Bellmunt J., Petrylak D. P. New therapeutic challenges in advanced bladder cancer. Seminars in Oncology. 2012;39(5):598–607. doi: 10.1053/j.seminoncol.2012.08.007. - DOI - PubMed
    1. Farina M. S., Lundgren K. T., Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs. 2017;77(10):1077–1089. doi: 10.1007/s40265-017-0748-7. - DOI - PubMed
    1. Loehrer P. J., Sr., Einhorn L. H., Elson P. J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. Journal of Clinical Oncology. 1992;10(7):1066–1073. doi: 10.1200/JCO.1992.10.7.1066. - DOI - PubMed

MeSH terms